Role of JAK/STAT3 Signaling in Functional Stimulation of Mesenchymal Progenitor Cells by Fibroblast Growth Factor


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

JAK/STAT signaling pathway was examined during functional stimulation of mesenchymal progenitor cells with fibroblast growth factor. The differences were observed in the realizations of the proliferation-differentiation potential of CFU-fibroblasts under blockade of JAKs or during selective inactivation of STAT3. The study revealed stimulating influences of JAKs and STAT3 on mitotic activity of progenitor cells and individual roles of these proteins in the control of their maturation. Blockade of JAKs diminished the level of fibroblast colony formation and the score of actively proliferating CFU-fibroblasts at the background increase of the differentiation rate of progenitor cells. In contrast, STAT3 inhibitor resulted in a coordinated decrease of all examined parameters.

About the authors

G. N. Zyuz’kov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; National Research Tomsk State University

Author for correspondence.
Email: zgn@pharmso.ru
Russian Federation, Tomsk; Tomsk

E. V. Udut

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

L. A. Miroshnichenko

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

T. Yu. Polyakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

E. V. Simanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

L. A. Stavrova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

G. A. Prosekin

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

M. Yu. Minakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

E. V. Borodulina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

I. V. Mareev

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

R. V. Gurto

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

V. V. Zhdanov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Russian Federation, Tomsk

V. V. Udut

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; National Research Tomsk State University

Email: zgn@pharmso.ru
Russian Federation, Tomsk; Tomsk


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies